# Phase 2 Trial to Evaluate Safety and Efficacy of Setmelanotide (RM-493) in Obese Participants With Prader-Willi Syndrome

> **NCT02311673** · PHASE2 · COMPLETED · sponsor: **Rhythm Pharmaceuticals, Inc.** · enrollment: 40 (actual)

## Conditions studied

- Prader-Willi Syndrome

## Interventions

- **DRUG:** Setmelanotide
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02311673
- **Lead sponsor:** Rhythm Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-03-19
- **Primary completion:** 2016-10-26
- **Final completion:** 2016-10-26
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2023-07-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02311673

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02311673, "Phase 2 Trial to Evaluate Safety and Efficacy of Setmelanotide (RM-493) in Obese Participants With Prader-Willi Syndrome". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02311673. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*